TY - JOUR T1 - Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer JF - In Vivo JO - In Vivo SP - 859 LP - 864 DO - 10.21873/invivo.12774 VL - 36 IS - 2 AU - SHINYA YAMAMOTO AU - TAKASHI CHISHIMA AU - YUKAKO SHIBATA AU - SHIORI INOUE AU - FUMI HARADA AU - HIDEKI TAKEUCHI AU - AKIMITSU YAMADA AU - KAZUTAKA NARUI AU - ITARU ENDO Y1 - 2022/03/01 UR - http://iv.iiarjournals.org/content/36/2/859.abstract N2 - Background/Aim: There are few models predicting breast cancer prognosis among patients receiving neoadjuvant chemotherapy (NAC) for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative (luminal) breast cancer. We examined whether biological features (BFs) of residual tumors are prognostic factors following NAC. Patients and Methods: We enrolled patients with remnant tumors following NAC for luminal breast cancer and evaluated clinical stage, pathological stage, BFs prior to NAC, and BFs following NAC as prognostic factors. BFs were divided into high and low risk using the previously reported YR-IHC4 model calculated according to ER, progesterone receptor (PgR), HER2, and the proliferation marker Ki-67. Results: A total of 57 patients were enrolled in the current study. We observed a statistically significant difference in relapse-free survival (RFS) between the BF risk categories via YR-IHC4 predictions following NAC (p=0.044). The 5-year RFS rates of the BF low- and high-risk groups following NAC were 84.2% and 52.5%, respectively. Conclusion: BFs of residual tumors following NAC may be important prognostic factors in luminal breast cancer. ER -